Pfizer and biontech announce positive early data from clinical trial of omicron ba.4/ba.5-adapted bivalent booster in individuals 18 years and older

New york & mainz, germany--(business wire)--pfizer inc. (nyse: pfe) and biontech se (nasdaq: bntx) today announced early data from a phase 2/3 clinical trial (nct05472038) evaluating the safety, tolerability, and immunogenicity of the companies' omicron ba.4/ba.5-adapted bivalent covid-19 vaccine (pfizer-biontech covid-19 vaccine, bivalent (original and omicron ba.4/ba.5)).
BNTX Ratings Summary
BNTX Quant Ranking